News Rumour of Pfizer, Seagen deal is true, with $43bn price tag Pfizer says Seagen's current and future drugs could add $10 billion to its revenues from 2030.
News Despite FDA doubts, advisors back first-line Polivy use Panel votes 11 to 2 to back Roche's drug for treatment-naïve diffuse large B-cell lymphoma.
News Could VR therapy improve mental health in cancer patients? Study is testing a VR DTx developed by Rocket VR Health and Massachusetts General Hospital.
News AZ cancer drugs chalk up wins in early-stage lung cancer Tagrisso and Imfinzi show benefit as neoadjuvant and adjuvant therapy for patients with NSLC.
News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
News FDA removes leash from Verzenio in early breast cancer Drug can now be used as adjuvant therapy without Ki-67 testing, taking a brake off prescribing.
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
